Group 1 - Immuron Limited (NASDAQ:IMRN) is a biotechnology company focused on developing medicines to prevent diarrhea, with a recent setback in its clinical trial for an ETEC hyperimmune bovine colostrum product, which failed to meet its primary endpoint, resulting in a 25.8% drop in share price [2] - The clinical trial was conducted by the Uniformed Services University to assess the product's effectiveness in maintaining gut health during travel and deployment, but Immuron stated that the results do not reflect the performance of its Travelan product due to non-compliance with administration rules and third-party manufacturing [2] - On November 5th, the FDA approved Immuron's IMM-529 drug for a phase 2 clinical trial targeting Clostridioides difficile infection, with the study expected to start in the first half of 2026 and enroll up to 60 participants [3]